UPDATE: Canaccord Genuity Decreases PT on Delcath Systems to $5

According to a research report this morning, Canaccord Genuity decreases its PT on Delcath Systems

from $8 to $5. Canaccord Genuity explained, ‘These physicians provided an interesting perspective about how CHEMOSAT fits in the oncology armamentarium. We reduce our forward estimates and price target – to $5.00 from $8.00 – to reflect dilution related to the recent equity offering and previously announced delay of the NDA filing (mid-August-E).” Delcath Systems closed Friday at $1.44 as Canaccord Genuity maintains its Buy rating.